Ovulatory effects of flutamide in the polycystic ovary syndrome

References

• Franks S. The polycystic ovary syndrome. New Engl J Med 1995;333:853–61
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000;21:347–62
   PubMed Web of Science ®Google Scholar
• Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003;101:995–1007
   PubMed Web of Science ®Google Scholar
• Azziz R, Zakur HA. 21-Hydroxilase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab 1989;69:577–84
   PubMed Web of Science ®Google Scholar
• Serafini P, Lobo RA. Increased 5-alpha reductase activity in idiopathic hirsutism. Fertil Steril 1985;43:74–8
   PubMed Web of Science ®Google Scholar
• Neri R, Florance K, Koziol P, Van Cleave S. A biological profile of a nonsteroidal antiandrogen, SCH13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Endocrinology 1972;91:427–37
   PubMed Web of Science ®Google Scholar
• Brogden RN, Clissold SP. Flutamide: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. Drugs 1989;38:185–203
   PubMed Web of Science ®Google Scholar
• Ayub M, Levell MJ. Inibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by antiandrogens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro. J Steroid Biochem 1987;28:43–7
   PubMedGoogle Scholar
• Brochu M, Bélanger A, Dupont A, et al. Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. J Steroid Biochem 1987;28:619–22
   PubMedGoogle Scholar
• Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304–10
   PubMed Web of Science ®Google Scholar
• Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006;91:3970–80
   PubMed Web of Science ®Google Scholar
• Calaf J, López E, Millet A, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 2007;92:3446–52
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Moyano D, Gómez O, Balasch J. Long-term safety and tolerability of flutamide for the treatment of hirsutism. Fertil Steril 2009;91:1183–8
   PubMed Web of Science ®Google Scholar
• Paradisi R, Venturoli S. Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period. Eur J Endocrinol 2010;163:139–47
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol 2002;57:231–4
   PubMed Web of Science ®Google Scholar
• Paradisi R, Fabbri R, Porcu E, et al. Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrea over a 15-year period. Gynecol Endocrinol 2011;27:823–9
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003;79:91–5
   PubMed Web of Science ®Google Scholar
• Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother 2011;45:469–75
   PubMed Web of Science ®Google Scholar
• Hatch R, Rosenfield R, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815–30
   PubMed Web of Science ®Google Scholar
• Paradisi R, Lodi S, Bolelli G, Venturoli S. Radioimmunoassay of three oestrogens and three androgens in the same plasma sample after extraction and chromatographic separation. Eur J Endocrinol 1980;94:229–34
   Google Scholar
• Moghetti P, Tosi F, Castello R, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952–60
   PubMed Web of Science ®Google Scholar
• Sir-Petermann T, Rabenbauer B, Wildt L. Endocrinology: the effect of flutamide on pulsatile gonadotropin secretion in hyperandrogenic women. Hum Reprod 1993;8:1807–12
   PubMedGoogle Scholar
• Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996;155:209–12
   PubMedGoogle Scholar
• de Zegher F, Ibanez L. Low-dose flutamide for hirsutism: into the limelight, at last. Nat Rev Endocrinol 2010;6:421–2
   PubMedGoogle Scholar
• Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradion and progesterone. J Clin Endocrinol Metab 2000;85:4047–52
   PubMed Web of Science ®Google Scholar